This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Cramer's Action Alerts PLUS - See his portfolio and get alerts BEFORE every trade. Learn more NOW!

John Garibotto Joins Cellnovo's Board Of Directors

SWANSEA, England, June 21, 2013 /PRNewswire/ --

Cellnovo, the leading innovator in mobile diabetes management technology, announced today the appointment of John Garibotto as non-executive director.

Mr. Garibotto is a 20 year veteran of the medical device industry and has been instrumental in the development, formation, and financing of highly successful medical device companies including Insulet Corporation (IPO May 2007, Nasdaq: PODD) and TransVascular, Inc. (acquired by Medtronic in Sept '04).  He is presently the founder and Chief Technology Officer of Securus Medical Group, Inc.  Mr. Garibotto has earned a B.Sc. in Industrial Technology from the University of Massachusetts at Lowell and a Masters in Business Administration from Northeastern University.

"It is a real pleasure to welcome John as director," said Eric Beard, Cellnovo's Executive Chairman.  "John has vast experience in complex medical device development.  His expertise and guidance will be invaluable as we prepare to submit our mobile-diabetes management system for US approval."

"I'm delighted to join the board of this outstanding company," said John Garibotto.  "Cellnovo has developed a game-changing approach to the treatment and follow up of patients with type 1 diabetes.  I am very impressed by the mobile, real-time technology that Cellnovo have used for their system, which will undoubtedly address the many unmet needs of both patient and care teams."

About Cellnovo

A UK-based medical device company, Cellnovo develops an innovative mobile diabetes management system. Comprised of a mobile connected patch pump, mobile touchscreen handset/controller, blood glucose meter and applications, the Cellnovo system provides intuitive operation, wireless Internet connectivity and real-time tracking, all industry firsts. For further information, please visit http://www.cellnovo.com.

SOURCE Cellnovo

Copyright 2011 PR Newswire. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 18,214.42 -10.15 -0.06%
S&P 500 2,110.74 -3.12 -0.15%
NASDAQ 4,987.89 +20.7530 0.42%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs